Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acriol Pro is a topical anesthetic cream containing a eutectic mixture of lidocaine (2.5%) and prilocaine (2.5%). Developed and manufactured by the Russian pharmaceutical company Akrikhin, it is a generic version of Emla. Acriol Pro is indicated for surface anesthesia of the skin and genital mucosa prior to painful dermatological, cosmetic, and minor surgical procedures, such as injections, vaccinations, catheterization, and epilation. The combination of lidocaine and prilocaine acts synergistically to block voltage-gated sodium channels in the neuronal membrane, preventing the generation and conduction of nerve impulses to provide effective local pain relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + prilocaine (Akrikhin).